Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a ‘substantial’ new contract by an existing ‘large pharma’ client, though doesn’t specify whom the client is. The project, which is valued at £178,000, involves involves pharmacokinetic-pharmacodynamic modelling in the field of DNA damage and repair fields. It is designed to help inform clinical dose and scheduling decisions. Physiomics expects this work to be completed over the course of the next six months.

Chief Executive Officer Peter Sargent says: ‘We are very pleased that we’ve been awarded this substantial project and we very much look forward to working with the client team on this exciting project.’

Current stock price: 1.35 pence, up 7.8% in London on Monday at noon

12-month change: down 68%

Copyright 2024 Alliance News Ltd. All Rights Reserved.